nach oben

Erschienen in:

23.04.2021 | Original Article

Appendiceal goblet cell carcinomas have poor survival despite completion surgery

verfasst von: Edward Alabraba, David Mark Pritchard, Rebecca Griffin, Rafael Diaz-Nieto, Melissa Banks, Daniel James Cuthbertson, Stephen Fenwick

Erschienen in: Endocrine | Ausgabe 3/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Appendiceal goblet cell carcinomas (aGCCs) are rare but aggressive tumours associated with significant mortality. We retrospectively reviewed the outcomes of aGCC patients treated at our tertiary referral centre.

Methods

We analysed aGCC patients, diagnosed between 1990–2016, assessing the impact of completion surgery and tumour factors on survival. Survival was assessed using Kaplan–Meier analysis.

Results

We identified 41 patients (23 F, 18 M); median age 61 (range 27–79) years. Mean tumour size was 10.5 (range 0.5–50) mm; most tumours were located in the appendiceal tip (n = 18, 45%). Appendicectomy was the index surgery in 32 patients, 24 of whom subsequently underwent completion surgery at median 3 (range 1.3–13.3) months later. Histology from completion surgery showed residual disease in 8 patients: nodal disease (n = 2) or residual tumour (n = 6). Index surgery for the rest was either colectomy (n = 7) or cytoreductive surgery plus intraperitoneal chemotherapy (CRS-HIPEC) (n = 1). Index and completion surgery had 0% mortality and 2.5% morbidity. Overall and recurrence-free survival were not significantly affected by tumour grade or completion surgery. Disease recurred in 9 patients after a median follow-up of 57.0 (4.6–114.9) months; 7 of these patients died during follow-up. Recurrences were treated with CRS-HIPEC (n = 1), palliative chemotherapy (n = 3) or supportive care (n = 5). Five- and ten- year overall survival were 85.3% and 62.3% respectively; 5-year and 10-year recurrence-free survival were 73.6% and 50.6%.

Conclusion

The prognosis of aGCCs remains relatively poor. Completion surgery did not prevent recurrence or improve survival, but this needs to be verified with a larger patient cohort. The high mortality associated with tumour recurrence questions current treatment recommendations.

M.L. McGory, M.A. Maggard, H. Kang, J.B. O’Connell, C.Y. Ko, Malignancies of the appendix: beyond case series reports. Dis. Colon Rectum. 48(12), 2264–2271 (2005). https://doi.org/10.1007/s10350-005-0196-4CrossRefPubMed

P. Roy, R. Chetty, Goblet cell carcinoid tumors of the appendix: an overview. World J. Gastrointest. Oncol. 2(6), 251–258 (2010). https://doi.org/10.4251/wjgo.v2.i6.251CrossRefPubMedPubMedCentral

M.E. McCusker, T.R. Cote, L.X. Clegg, L.H. Sobin, Primary malignant neoplasms of the appendix: a population-based study from the surveillance, epidemiology and end-results program, 1973-1998. Cancer 94(12), 3307–3312 (2002). https://doi.org/10.1002/cncr.10589CrossRefPubMed

A. Lamarca, D. Nonaka, C. Lopez Escola, R.A. Hubner, S. O’Dwyer, B. Chakrabarty et al. Appendiceal goblet cell carcinoids: management considerations from a reference peritoneal tumour service centre and ENETS centre of excellence. Neuroendocrinology 103(5), 500–517 (2016). https://doi.org/10.1159/000440725CrossRefPubMed

U.F. Pape, A. Perren, B. Niederle, D. Gross, T. Gress, F. Costa et al. ENETS Consensus Guidelines for the management of patients with neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas. Neuroendocrinology 95(2), 135–156 (2012). https://doi.org/10.1159/000335629CrossRefPubMed

U.F. Pape, B. Niederle, F. Costa, D. Gross, F. Kelestimur, R. Kianmanesh et al. ENETS consensus guidelines for neuroendocrine neoplasms of the appendix (excluding goblet cell carcinomas). Neuroendocrinology 103(2), 144–152 (2016). https://doi.org/10.1159/000443165CrossRefPubMed

J.P. Boudreaux, D.S. Klimstra, M.M. Hassan, E.A. Woltering, R.T. Jensen, S.J. Goldsmith et al. The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the Jejunum, Ileum, Appendix, and Cecum. Pancreas 39(6), 753–766 (2010). https://doi.org/10.1097/MPA.0b013e3181ebb2a5CrossRefPubMed

UKINETS. UKINETS bitesize guidance: Goblet Cell Carcinoma, 2016, http://www.ukinets.org/wp-content/uploads/UKINETS-bitesize-guidance-GCC.pdf

B. Varisco, B. McAlvin, J. Dias, D. Franga, Adenocarcinoid of the appendix: is right hemicolectomy necessary? A meta-analysis of retrospective chart reviews. Am. Surg. 70(7), 593–599 (2004)PubMed

10.

Bosman FT, Carneiro F, Hruban RH, Theise ND. WHO Classification of Tumours of the Digestive System. 5th ed. Lyon: International Agency for Research on Cancer; 2019. pp. 135–152

11.

K.W. Wen, G. Hale, N. Shafizadeh, M. Hosseini, A. Huang, S. Kakar, Appendiceal goblet cell carcinoid: common errors in staging and clinical interpretation with a proposal for an improved terminology. Hum. Pathol. 65, 187–193 (2017). https://doi.org/10.1016/j.humpath.2017.05.012CrossRefPubMed

12.

E. Liu, D.A. Telem, R.R. Warner, A. Dikman, C.M. Divino, The role of Ki-67 in predicting biological behavior of goblet cell carcinoid tumor in appendix. Am. J. Surg. 202(4), 400–403 (2011). https://doi.org/10.1016/j.amjsurg.2010.08.036CrossRefPubMed

13.

D. Dindo, N. Demartines, P.A. Clavien, Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann. Surg. 240(2), 205–213 (2004). https://doi.org/10.1097/01.sla.0000133083.54934.aeCrossRefPubMedPubMedCentral

14.

L.H. Tang, J. Shia, R.A. Soslow, D. Dhall, W.D. Wong, E. O’Reilly et al. Pathologic classification and clinical behavior of the spectrum of goblet cell carcinoid tumors of the appendix. Am. J. surgical Pathol. 32(10), 1429–1443 (2008). https://doi.org/10.1097/PAS.0b013e31817f1816CrossRef

15.

T.H. Pham, B. Wolff, S.C. Abraham, E. Drelichman, Surgical and chemotherapy treatment outcomes of goblet cell carcinoid: a tertiary cancer center experience. Ann. surgical Oncol. 13(3), 370–376 (2006). https://doi.org/10.1245/aso.2006.02.016CrossRef

16.

S. Shenoy, Goblet cell carcinoids of the appendix: tumor biology, mutations and management strategies. World J. Gastrointest. Surg. 8(10), 660–669 (2016). https://doi.org/10.4240/wjgs.v8.i10.660CrossRefPubMedPubMedCentral

17.

M.W. Taggart, S.C. Abraham, M.J. Overman, P.F. Mansfield, A. Rashid, Goblet cell carcinoid tumor, mixed goblet cell carcinoid-adenocarcinoma, and adenocarcinoma of the appendix: comparison of clinicopathologic features and prognosis. Arch. Pathol. Lab Med. 139(6), 782–790 (2015). https://doi.org/10.5858/arpa.2013-0047-OACrossRefPubMed

18.

R.E. Rossi, T.V. Luong, M.E. Caplin, C. Thirlwell, T. Meyer, J. Garcia-Hernandez et al. Goblet cell appendiceal tumors-management dilemmas and long-term outcomes. Surgical Oncol. 24(1), 47–53 (2015). https://doi.org/10.1016/j.suronc.2015.01.001CrossRef

19.

A.K. Clift, O. Kornasiewicz, P. Drymousis, O. Faiz, H.S. Wasan, J.M. Kinross et al. Goblet cell carcinomas of the appendix: rare but aggressive neoplasms with challenging management. Endocr. Connect. 7(2), 268–277 (2018). https://doi.org/10.1530/ec-17-0311CrossRefPubMedPubMedCentral

20.

P. Bucher, P. Gervaz, F. Ris, W. Oulhaci, J.F. Egger, P. Morel, Surgical treatment of appendiceal adenocarcinoid (goblet cell carcinoid). World J. Surg. 29(11), 1436–1439 (2005). https://doi.org/10.1007/s00268-005-7958-yCrossRefPubMed

21.

J.C. Byrn, J.L. Wang, C.M. Divino, S.Q. Nguyen, R.R. Warner, Management of goblet cell carcinoid. J. Surg. Oncol. 94(5), 396–402 (2006). https://doi.org/10.1002/jso.20587CrossRefPubMed

22.

W. Shaib, K. Krishna, S. Kim, M. Goodman, J. Rock, Z. Chen et al. Appendiceal neuroendocrine, goblet and signet-ring cell tumors: a spectrum of diseases with different patterns of presentation and outcome. Cancer Res Treat. 48(2), 596–604 (2016). https://doi.org/10.4143/crt.2015.029CrossRefPubMed

23.

C. Toumpanakis, R.A. Standish, E. Baishnab, M.C. Winslet, M.E. Caplin, Goblet cell carcinoid tumors (adenocarcinoid) of the appendix. Dis. Colon Rectum 50(3), 315–322 (2007). https://doi.org/10.1007/s10350-006-0762-4CrossRefPubMed

24.

I.H. Olsen, N. Holt, S.W. Langer, J.P. Hasselby, H. Grønbæk, J. Hillingsø et al. Goblet cell carcinoids: characteristics of a Danish cohort of 83 patients. PloS One 10(2), e0117627 (2015). https://doi.org/10.1371/journal.pone.0117627CrossRefPubMedPubMedCentral

25.

Y.J. McConnell, L.A. Mack, X. Gui, N.J. Carr, L. Sideris, W.J. Temple et al. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: an emerging treatment option for advanced goblet cell tumors of the appendix. Ann. Surgical Oncol. 21(6), 1975–1982 (2014). https://doi.org/10.1245/s10434-013-3469-5CrossRef

26.

H.H. Yu, Y. Yonemura, M.C. Hsieh, A. Mizumoto, S. Wakama, C.Y. Lu, Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for appendiceal goblet cell carcinomas with peritoneal carcinomatosis: results from a single specialized center. Cancer Manag Res. 9, 513–523 (2017). https://doi.org/10.2147/cmar.S147227CrossRefPubMedPubMedCentral

27.

D. Nonaka, G. Papaxoinis, A. Lamarca, P. Fulford, J. Valle, B. Chakrabarty, A study of appendiceal crypt cell adenocarcinoma (so-called goblet cell carcinoid and its related adenocarcinoma). Hum. Pathol. 72, 18–27 (2018). https://doi.org/10.1016/j.humpath.2017.08.005CrossRefPubMed

28.

E.S. Tsang, Y.J. McConnell, D.F. Schaeffer, L. Lee, Y. Yin, S. Zerhouni et al. Outcomes of surgical and chemotherapeutic treatments of goblet cell carcinoid tumors of the appendix. Ann. Surgical Oncol. 25(8), 2391–2399 (2018). https://doi.org/10.1245/s10434-018-6560-0CrossRef

29.

A.H. Madsen, M. Ladekarl, G.E. Villadsen, H. Grønbæk, M.M. Sørensen, K. Stribolt et al. Effects of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of goblet cell carcinoma: a prospective cohort study. Ann. surgical Oncol. 25(2), 422–430 (2018). https://doi.org/10.1245/s10434-017-6272-xCrossRef

30.

M.E. O’Donnell, J. Carson, W.I. Garstin, Surgical treatment of malignant carcinoid tumours of the appendix. Int. J. Clin. Pract. 61(3), 431–437 (2007). https://doi.org/10.1111/j.1742-1241.2006.00875.xCrossRefPubMed

31.

C.C. Li, M. Hirowaka, Z.R. Qian, B. Xu, T. Sano, Expression of E-cadherin, b-catenin, and Ki-67 in goblet cell carcinoids of the appendix: an immunohistochemical study with clinical correlation. Endocr. Pathol. 13(1), 47–58 (2002). https://doi.org/10.1385/ep:13:1:47CrossRefPubMed

32.

R. Kanthan, A. Saxena, S.C. Kanthan, Goblet cell carcinoids of the appendix: immunophenotype and ultrastructural study. Arch. Pathol. Lab Med 125(3), 386–390 (2001). https://doi.org/10.1043/0003/9985(2001)125<0386:Gccota>2.0.Co;22.0.Co;2.

33.

D.M. Ramnani, I.I. Wistuba, C. Behrens, A.F. Gazdar, L.H. Sobin, J. Albores-Saavedra, K-ras and p53 mutations in the pathogenesis of classical and goblet cell carcinoids of the appendix. Cancer. 86(1), 14–21 (1999). https://doi.org/10.1002/(sici)1097-0142(19990701)86:1<14::aid-cncr4>3.0.co;2-x.

34.

J.A. Butler, A. Houshiar, F. Lin, S.E. Wilson, Goblet cell carcinoid of the appendix. Am. J. Surg. 168(6), 685–687 (1994). https://doi.org/10.1016/s0002-9610(05)80145-xCrossRefPubMed

Titel: Appendiceal goblet cell carcinomas have poor survival despite completion surgery
verfasst von: Edward Alabraba
David Mark Pritchard
Rebecca Griffin
Rafael Diaz-Nieto
Melissa Banks
Daniel James Cuthbertson
Stephen Fenwick
Publikationsdatum: 23.04.2021
Verlag: Springer US
Erschienen in: Endocrine / Ausgabe 3/2021
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-021-02727-9

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Appendiceal goblet cell carcinomas have poor survival despite completion surgery